# Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-versus-docetaxel-in-a-predominantly-chinese-patient-population-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yi‐Long Wu,Shun Lü,Ying Cheng,Caicun Zhou,Jie Wang,Tony Mok,Li Zhang,Hai-Yan Tu,Lin Wu,Jifeng Feng,Yiping Zhang,Alexander Luft,Jianying Zhou,Zhiyong Ma,You Lü,Chengping Hu,Yuankai Shi,Christine Baudelet,Junliang Cai,Jianhua Chang |
| Citations | 362 |
| DOI | 10.1016/j.jtho.2019.01.006 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2908684819 |
| PMID | 30659987 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)
- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Lin Wu](https://scholariq.org/researchers/lin-wu/)
- [You Lü](https://scholariq.org/researchers/you-lu/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.